Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Space & Defense Innovation ETF (ARKX) vs BridgeBio Pharma Inc (BBIO) Price & Performance

ARK Space & Defense Innovation ETFTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

ARK Space & Defense Innovation ETF vs BridgeBio Pharma Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.41, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.

ARKXBBIO
Sector
Sector/ThematicHealth
52-Week High
$37.74$90.17
52-Week Low
$25.46$47.29
Market Cap
$16.61B
Enterprise Value
$18.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Space & Defense Innovation ETF

ARKX trades at $34.27, up 3.82% today, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 suggests overbought conditions. The ETF focuses on space exploration and innovation, holding positions in companies like SpaceX and Rocket Lab, benefiting from strong sector tailwinds and recent SpaceX IPO momentum.

Outlook is positive due to growth in the space economy, but risks include high volatility and stretched valuations in key holdings. Investors should weigh exposure to speculative tech against potential regulatory and competitive pressures in the evolving market.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Space & Defense Innovation ETF

ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.

Read more on ARKX

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO